Genoox in the news

Healthcare investor Triventures backs genomics company Genoox in $6 million funding round

Triventures, Leading Healthcare Investor, Backs Genoox in $6 Million Funding Round

PALO ALTO, Calif. – (Business Wire) – Genoox, a genomic analysis company making it easier for doctors, clinicians and researchers to analyze and act on genetic sequencing results by applying various clinical applications, today announced it closed a $6 million funding round. The round was led by Triventures, a venture capital fund that invests in transformational health startups led by elite teams and is focused on impacting the quality, cost and experience of healthcare. The investment was joined by Inimiti Capital and Glilot Capital Partners.

Genoox, Bionano Genomics Partner to Improve DNA Structural Variant Disease Detection

Michigan genomic research lab protects data with de-indentifier, multilayer platform

The Genoox platform helps the team apply standards for both security policies and sharing data across the community, which has the benefit of increasing cooperation between organizations

The Importance Of Data Governance In The Future Of Healthcare

Genoox will analyze genetic data captured and provide actionable insights to hospitals, clinical labs and researchers throughout Israel

Genoox Betting On Variant Classification Tech to Bring More NGS to Community Hospitals

Genoox has developed an artificially intelligent engine to classify genetic variants, based on American College of Medical Genetics and Genomics guidelines. This platform provides data analytics services to physicians and researchers looking to integrate genomic sequencing information into clinical workflows, and Genoox has said its technology can lower sequencing costs by as much as 90 percent and reduce turnaround time to a few minutes rather than hours or days.

Genoox raises $6M to make genetic data analysis more accessible for clinics

Genoox’s current platform can examine data from both whole-genome sequencing (WGS), which sequences all the base pairs in a genome at one time, as well as whole-exome sequencing (WES), a less costly alternative to whole-genome sequencing that sequences exons, which make up about one percent of the human genome.

Analytics Startup Genoox Lands $6M Investment, Enters US Market

The firm provides data analytics to help physicians and researchers integrate genomic sequencing information into clinical workflows. The technology supports next-generation sequencing. The company claims that its technology can lower sequencing costs by as much as 90 percent and reduce turnaround time to a few minutes rather than hours or days.